Biodexa Ebitda from 2010 to 2024

BDRX Stock   4.93  0.13  2.71%   
Biodexa Pharmaceticals EBITDA yearly trend continues to be fairly stable with very little volatility. EBITDA will likely drop to about -7.5 M in 2024. During the period from 2010 to 2024, Biodexa Pharmaceticals EBITDA regression line of annual values had significance of  0.12 and arithmetic mean of (7,956,603). View All Fundamentals
 
EBITDA  
First Reported
2013-03-31
Previous Quarter
-2.1 M
Current Value
-2.1 M
Quarterly Volatility
1.5 M
 
Yuan Drop
 
Covid
Check Biodexa Pharmaceticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biodexa Pharmaceticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 268.9 K, Selling General Administrative of 3.9 M or Other Operating Expenses of 11.7 M, as well as many indicators such as Price To Sales Ratio of 4.15, Dividend Yield of 0.0 or PTB Ratio of 0.34. Biodexa financial statements analysis is a perfect complement when working with Biodexa Pharmaceticals Valuation or Volatility modules.
  
Check out the analysis of Biodexa Pharmaceticals Correlation against competitors.
For more information on how to buy Biodexa Stock please use our How to Invest in Biodexa Pharmaceticals guide.

Latest Biodexa Pharmaceticals' Ebitda Growth Pattern

Below is the plot of the Ebitda of Biodexa Pharmaceticals over the last few years. It is Biodexa Pharmaceticals' EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Biodexa Pharmaceticals' overall financial position and show how it may be relating to other accounts over time.
Ebitda10 Years Trend
Slightly volatile
   Ebitda   
       Timeline  

Biodexa Ebitda Regression Statistics

Arithmetic Mean(7,956,603)
Coefficient Of Variation(58.62)
Mean Deviation3,125,464
Median(7,394,000)
Standard Deviation4,664,468
Sample Variance21.8T
Range18.4M
R-Value(0.42)
Mean Square Error19.4T
R-Squared0.17
Significance0.12
Slope(433,512)
Total Sum of Squares304.6T

Biodexa Ebitda History

2024-7.5 M
2023-7.2 M
2022-7.4 M
2021-5.7 M
2020-22.2 M
2019-10.3 M
2018-10.7 M

About Biodexa Pharmaceticals Financial Statements

Biodexa Pharmaceticals investors use historical fundamental indicators, such as Biodexa Pharmaceticals' Ebitda, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Biodexa Pharmaceticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EBITDA-7.2 M-7.5 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Biodexa Stock Analysis

When running Biodexa Pharmaceticals' price analysis, check to measure Biodexa Pharmaceticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biodexa Pharmaceticals is operating at the current time. Most of Biodexa Pharmaceticals' value examination focuses on studying past and present price action to predict the probability of Biodexa Pharmaceticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biodexa Pharmaceticals' price. Additionally, you may evaluate how the addition of Biodexa Pharmaceticals to your portfolios can decrease your overall portfolio volatility.